Clinical trials: Cystic Fibrosis Gastrointestinal Disease
Cystic Fibrosis
Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers
This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of SPL84 single ascending doses (SAD) in healthy volunteers (HV)
- Trial name
- NCT06217952
- Testing
- SPL84
- Where
- Israel
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- SpliSense Ltd.
Cystic Fibrosis
Probiotics in Cystic Fibrosis
Cystic fibrosis (CF) is a complex systemic disease that mainly involves the respiratory and gastrointestinal (GI) tracts. The polymicrobial community composition of respiratory and GI tracts is influenced by both genetic and…
- Trial name
- NCT01956916
- Testing
- Lactobacillus rhamnosus GG
- Where
- 5 sites in Italy
- Volunteers
- 110 people
- Sponsor
- Federico II University
Cystic Fibrosis, Chronic Disease
Feasibility of a Goal-based Agenda Setting Intervention
This study aims to assess the feasibility of a new, brief intervention, the 'coopeRATE Prompt', for informing conversations between patients and physicians in routine tele-health and in-person adult Cystic Fibrosis (CF) care.
- Trial name
- NCT04696484
- Testing
- coopeRATE Prompt
- Where
- 4 sites in United States
- Volunteers
- 219 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Cystic Fibrosis
Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF
Cystic fibrosis has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections.
- Trial name
- CF-AOX (NCT02690064)
- Testing
- Acute Antioxidant, Chronic Antioxidant
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Augusta University
Cystic Fibrosis
Pharmacokinetic Study of Lansoprazole in Cystic Fibrosis
The disposition of a number of drugs has been reported to be altered in patients with Cystic Fibrosis (CF). Changes in pharmacokinetic parameters observed included increased volumes of distribution and increased clearance of…
- Trial name
- NCT00458614
- Testing
- Lansoprazole
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Arkansas Children's Hospital Research Institute
Cystic Fibrosis, Cystic Fibrosis Gastrointestinal Disease
Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs
This is a Phase 2 study sponsored by AzurRx SAS and involves testing of a new medication for the compensation of exocrine pancreatic insufficiency (EPI) caused by cystic fibrosis (CF).
- Conditions
- Cystic Fibrosis, Cystic Fibrosis Gastrointestinal Disease, Cystic Fibrosis of Pancreas
- Trial name
- NCT04302662
- Testing
- MS1819-SD
- Where
- 10 sites in Hungary, Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- AzurRx SAS
Cystic Fibrosis
Growth Hormone Use in Cystic Fibrosis - a Multicenter Study
Cystic Fibrosis (CF) is the most common lethal genetic disorder in America. Previous studies by our group and others have shown that human recombinant growth hormone (GH) improves height velocity, weight velocity, lean body mass…
- Trial name
- NCT00005112
- Testing
- Human recombinant growth hormone
- Where
- 2 sites in United States
- Sponsor
- National Center for Research Resources (NCRR)
Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
This study will assess the safety and tolerability of pancrelipase delayed release capsules in subjects up to 6 years of age with Pancreatic Exocrine Insufficiency (PEI) due to Cystic Fibrosis.
- Trial name
- NCT00775528
- Testing
- Pancrelipase Delayed Release
- Where
- 12 sites in United States
- Volunteers
- 19 people
- Sponsor
- Solvay Pharmaceuticals
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Semaglutide in CFRD
This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).
- Trial name
- NCT05788965
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Minnesota
Cystic Fibrosis
Can Quantitative Ultrasound be Used for the Evaluation of Bone Health in Adolescents and Adults With Cystic Fibrosis
Measurement of bone density of Cystic Fibrosis patients with two techniques and correlation to serum bone parameters, use of steroids, lung function and nutritional status.
- Trial name
- NCT00221572
- Testing
- Determination of bot density of Cystic Fibrosis patients
- Where
- Belgium
- Volunteers
- 68 people
- Sponsor
- University Hospital, Ghent
Cystic Fibrosis
Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)
This is a study to examine the effect of combining chronic oral azithromycin with inhaled tobramycin in adolescent and adult subjects with cystic fibrosis who are chronically infected with P. aeruginosa.
- Trial name
- TEACH (NCT02677701)
- Testing
- azithromycin, inhaled tobramycin
- Where
- 39 sites in United States
- Volunteers
- 119 people
- Sponsor
- Seattle Children's Hospital
Cystic Fibrosis
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
- Trial name
- NCT05504837
- Testing
- KB407 (Nebulization)
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Krystal Biotech, Inc.
Cystic Fibrosis
Assessment of Inflammatory Mediators (AIM)
Specific Aim: To determine whether neutrophils, active elastase, and cytokines measured in sputum induced using hypertonic saline are useful screening tests for determining if a particular agent with known anti-inflammatory…
- Trial name
- NCT00219895
- Testing
- Ibuprofen
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Ramsey, Bonnie, MD
Cystic Fibrosis
Improving Therapeutic Adherence With a Co-constructed Program Involving Both Patients and Health Care Professionals
Background Cystic fibrosis is a life-threatening genetic disorder responsible for pulmonary failure and multi-systemic complications involving specific and large medical care burden.
- Trial name
- NCT03226795
- Testing
- " Information-Motivation-Behavioral skills " intervention.
- Where
- 3 sites in France
- Volunteers
- 450 people
- Sponsor
- Hospices Civils de Lyon
COPD, Cystic Fibrosis
Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation
The purpose of this study is to determine if the drug Plerixafor (Mozobil) can lead to clinically relevant efflux of CD117+ stem cells from the bone marrow to the peripheral blood of normal controls and patients awaiting lung…
- Conditions
- COPD, Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- NCT01916577
- Testing
- Plerixafor mobilization of autologous CD117 stem cells
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
This multicenter cross-sectional study will include a diverse population of adolescents and adults with CF. The overall Aim is to describe prevalence of diabetes microvascular complications and macrovascular surrogates in people…
- Conditions
- Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes, Diabetes, Retinopathy
- Trial name
- SPeCTRuM (NCT06837181)
- Testing
- observational study
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Jaeb Center for Health Research
Cystic Fibrosis
LBM & Lung Function in Adolescents With CF
In patients with cystic fibrosis (CF) the commonest cause of death is respiratory failure. Respiratory failure can have many causes.
- Trial name
- NCT02797912
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- King's College Hospital NHS Trust
Cystic Fibrosis
Airway Clearance for Pediatric and Adult Cystic Fibrosis Patients Using a Portable Intra-Pulmonary Percussion Device
This is a pilot study where the investigators aim to compare initial use of the standard airway clearance device (SACD), most commonly used being High frequency vest airway clearance system (VEST) with subsequent use of a…
- Trial name
- NCT04743206
- Testing
- Standard Airway Clearance device, Portable Internal Airway Percussion device
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Florida
Cystic Fibrosis, Pancreatic Insufficiency
Effect of Chronic Incretin-based Therapy in Cystic Fibrosis
In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop.
- Trial name
- NCT01879228
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Pennsylvania
Cystic Fibrosis
Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations
The investigators aim to assess whether pulmonary MRI (hyperpolarised 129Xe ventilation imaging [Xe-MRI]) can detect changes in ventilation defects in patients with CF before and after treatment for a pulmonary exacerbation.
- Trial name
- NCT02606487
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- The Hospital for Sick Children
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.